Cempra, Inc. (CEMP)

[agamemnus]

IV would be too expensive to enroll. Better get the sales first.

You can bet there will be a new adcom once they finish the trial. In the first adcom, the result was actually much better than what the FDA suggested. A couple thousand, many voting "no" said. There will be no label restrictions after the new adcom and it will be the new standard, surpassing zithro/azitromycin sales.

Finally: IV is expensive per patient, but a much smaller market.